Women with gene mutation may respond to chemotherapy differentlyBMJ 2001; 322 doi: https://doi.org/10.1136/bmj.322.7290.818/c (Published 07 April 2001) Cite this as: BMJ 2001;322:818
- Deborah Josefson
- San Francisco
Women who harbour mutations in BRCA1, a gene implicated in some types of hereditary breast cancer, may respond differently to chemotherapy from those lacking such mutations, a new study has found.
Researchers from Thomas Jefferson University Medical Center in Philadelphia, Pennsylvania, and the Burnham Institute in LaJolla, California, presented these findings recently at the annual meeting of the American Association for Cancer Research in New Orleans, Louisiana.
The work highlights the heterogeneity of cancers and the emergence of pharmacogenomics, foretelling a time when chemotherapeutic regimens will be tailor made according to the individual genetic profiles of patients and …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial